3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Recruiting
1
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Leukemia, Myeloid, Acute
28
Myelodysplastic Syndromes
19
Precursor Cell Lymphoblastic Leukemia-Lymphoma
18
Leukemia, Lymphocytic, Chronic, B-Cell
13
Lymphoma, Non-Hodgkin
12
Lymphoma
12
Recurrence
11
Multiple Myeloma
11
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
11
Leukemia
9
Leukemia, Biphenotypic, Acute
8
Ovarian Neoplasms
7
Neoplasms
7
Lymphoma, Mantle-Cell
7
Myeloproliferative Disorders
6
Melanoma
6
Lymphoma, Large B-Cell, Diffuse
6
Lymphoma, B-Cell
6
Hodgkin Disease
6
Hematologic Neoplasms
6
Lymphoma, Follicular
5
Immunoproliferative Disorders
5
Immune System Diseases
5
Lymphoproliferative Disorders
4
Lymphoma, B-Cell, Marginal Zone
4
Lymphatic Diseases
4
Carcinoma, Non-Small-Cell Lung
4
Sarcoma
3
Mesothelioma
3
Lung Neoplasms
3
Interventions
cabozantinib
2
pembrolizumab
1
lenvatinib
1
fludarabine
1
Selenomethionine
1
Nivolumab
1
Ipilimumab
1
Everolimus
1
Cyclophosphamide
1
CTLA-4 Antigen
1
Axitinib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Active not recruiting
×
Clear-cell metastatic renal cell carcinoma
×
fludarabine
×
Clear all
NCT04696731
2025-09-25
TRAVERSE
Allogene Therapeutics
Phase 1
Active not recruiting
120 enrolled